2-溴-1-(3-(三氟甲基)苯基)乙酮是一种含三氟甲氧基化合物，具有较高的膜渗透性、抗代谢稳定性及与脂膜的亲和力、热稳定性和化学稳定性等特点，被广泛应用于医药化工行业。制备：往装有尾气吸收装置、回流冷凝管、温度计的100 mL三颈烧瓶中依次加入1-(3-(三氟甲基)苯基)乙酮、溴酸钠、溴化钠和四氯化碳，搅拌、加热至回流，缓慢滴加1/2体积的硫酸(60 mmol浓硫酸用2 mL水稀释所得)，用气相色谱跟踪，底物完全参与反应后(约1 h)，快速加入1/3体积的引发剂溶液(1.1 g偶氮二异庚腈，用7 mL四氯化碳溶解所得)，体系出现剧烈回流后，继续缓慢滴加剩余的引发剂溶液和硫酸(约4.5 h内加完)，继续反应至产物不再形成或副产物明显增加时(约1.5 h)，降至室温、过滤，有机相用10 mL 5%的碳酸氢钠溶液洗涤、分液，有机相用无水硫酸钠干燥、浓缩，得到粗产品，经柱层析纯化（乙酸乙酯：石油醚=1：20）的洗脱液洗脱，浓缩，得到2-溴-1-(3-(三氟甲基)苯基)乙酮。
医药化工
合成路线 1（2003-10-3）
- 步骤：在冰冷却下，向市售的3'-三氟甲基苯乙酮（79.6g，0.423mol）的甲苯溶液（423mL）中加入过溴化吡啶鎓（135.4g，0.423mol）；搅拌5小时，同时加热至室温；将反应液再次用冰冷却，然后滴加400mL蒸馏水以停止反应和分馏；用400mL饱和碳酸氢钠水溶液洗涤甲苯层，然后用无水硫酸镁干燥，减压浓缩，减压蒸馏，得到目标化合物。
- 条件：With pyridinium perbromide hydrobromide In toluene at 0 - 20℃; for 5 h;
- 收率：81.7%
- 参考文献：[1] Journal of Medicinal Chemistry, 1995, vol. 38, #1, p. 34 - 41 [2] Journal of Organic Chemistry, 1980, vol. 45, #24, p. 4989 - 4990 [3] Journal fuer Praktische Chemie/Chemiker-Zeitung, 1998, vol. 340, #7, p. 649 - 655 [4] Journal of Medicinal Chemistry, 2014, vol. 57, #15, p. 6572 - 6582 [5] Patent: EP1571148, 2005, A1. Location in patent: Page/Page column 28 [6] Patent: WO2005/121105, 2005, A1. Location in patent: Page/Page column 16 [7] Patent: WO2008/140947, 2008, A1. Location in patent: Page/Page column 56 [8] Tetrahedron, 2008, vol. 64, #22, p. 5191 - 5199 [9] ACS Medicinal Chemistry Letters, 2016, vol. 7, #7, p. 686 - 691 [10] Journal of medicinal chemistry, 1972, vol. 15, #9, p. 989 - 994 [11] Journal of Heterocyclic Chemistry, 1981, vol. 18, p. 451 - 453 [12] Journal of Physical Chemistry, 1995, vol. 99, #20, p. 8190 - 8195 [13] Chemical & Pharmaceutical Bulletin, 1995, vol. 43, #9, p. 1497 - 1504 [14] Journal of the Chemical Society - Perkin Transactions 1, 1999, #17, p. 2421 - 2423 [15] Arzneimittel-Forschung/Drug Research, 2001, vol. 51, #7, p. 569 - 573 [16] Patent: US4968707, 1990, A [17] Bioorganic and Medicinal Chemistry, 2008, vol. 16, #17, p. 8187 - 8195 [18] Patent: US2004/6058, 2004, A1. Location in patent: Page/Page column 92 [19] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, #4, p. 1432 - 1435 [20] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, #1, p. 182 - 185 [21] Patent: WO2012/6473, 2012, A1. Location in patent: Page/Page column 55-56 [22] Patent: WO2012/100734, 2012, A1. Location in patent: Page/Page column 26 [23] Antimicrobial Agents and Chemotherapy, 2014, vol. 58, #7, p. 4242 - 4245 [24] Journal of Medicinal Chemistry, 2014, vol. 57, #12, p. 5226 - 5237 [25] European Journal of Medicinal Chemistry, 2015, vol. 99, p. 14 - 35 [26] Chemical Biology and Drug Design, 2015, vol. 86, #4, p. 849 - 856 [27] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, #15, p. 3669 - 3674 [28] Organic Letters, 2017, vol. 19, #8, p. 1994 - 1997 [29] Patent: CN107266413, 2017, A. Location in patent: Paragraph 0137; 0139; 0140; 0141 [30] Advanced Synthesis and Catalysis, 2018, vol. 360, #8, p. 1628 - 1633 [31] Patent: WO2009/146358, 2009, A1. Location in patent: Page/Page column 68
